Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 17/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 10/20 | 0.43 |
| ▸ | ACVR2A | P27037 | 2/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995011 | 1.00 | F11 (0.43) | F11KLKB1ACVR2ATGFBR2CNR1 | |
| SCHEMBL30995026 | 0.88 | F11 (0.44) | F11KLKB1ACVR2ATGFBR2CNR1 | |
| SCHEMBL31252194 | 0.85 | F11 (0.45) | F11KLKB1CYP3A4 | |
| SCHEMBL24633397 | 0.85 | F11 (0.43) | F11KLKB1CYP3A4 | |
| SCHEMBL29227917 | 0.84 | CNR1 (0.42) | F11KLKB1CNR1CYP3A4 | |
| SCHEMBL16972351 | 0.82 | F11 (0.41) | F11KLKB1CYP3A4 | |
| SCHEMBL29227939 | 0.81 | F11 (0.45) | F11KLKB1 | |
| SCHEMBL30995053 | 0.81 | F11 (0.45) | F11KLKB1 | |
| SCHEMBL30994984 | 0.81 | F11 (0.43) | F11KLKB1CYP3A4 | |
| SCHEMBL29227906 | 0.81 | F11 (0.43) | F11KLKB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126046-A | Substituted macrocyclic compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2022222960-A1 | FXIA INHIBITOR AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2022-10-27 | — | — | WO | disclosed |